Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer

Core Insights - Coherus Oncology has appointed Arvind Sood as Chief Strategy and Corporate Affairs Officer to enhance its strategic functions and investor relations [1][2] - The company is focused on advancing its innovative cancer therapeutics, particularly LOQTORZI® and its pipeline candidates, which target various cancers [2][3] - Coherus holds global rights to key products, CHS-114 and casdozokitug, which presents potential business development opportunities [2][4] Company Overview - Coherus Oncology is a commercial-stage innovative oncology company with an approved PD-1 inhibitor, LOQTORZI®, and a pipeline that includes mid-stage clinical candidates targeting multiple cancers [3] - The company's strategy includes growing LOQTORZI sales in nasopharyngeal carcinoma and developing new indications in combination with pipeline candidates [3] Pipeline Development - Coherus' pipeline features multiple antibody immunotherapy candidates aimed at enhancing immune responses against cancer [4] - CHS-114 is currently in Phase 1b/2a studies for advanced solid tumors, while casdozokitug is being evaluated in a Phase 2 study for hepatocellular carcinoma [4]